Drugs for Inappropriate Adh Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 12)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Empagliflozin |
Approved |
Phase 4 |
|
864070-44-0 |
73151030 11949646 |
Synonyms:
(1S)-1,5-ANHYDRO-1-(4-CHLORO-3-{4-[(3S)-TETRAHYDROFURAN-3-YLOXY]BENZYL}PHENYL)-D-GLUCITOL
(1S)-1,5-ANHYDRO-1-C-{4-CHLORO-3-((4-{((3S)-OXOLAN-3-YL)OXY}PHENYL)METHYL)PHENYL}-D-GLUCITOL
1-CHLORO-4-(GLUCOPYRANOS-1-YL)-2-(4-(TETRAHYDROFURAN-3-YLOXY)BENZYL)BENZENE
BI 10773
BI 10773|Jardiance®
BI10773
|
BI-10773
EMPAGLIFLOZIN
Empagliflozina
Empagliflozine
Empagliflozinum
JARDIANCE
|
|
2 |
|
Sodium-Glucose Transporter 2 Inhibitors |
|
Phase 4 |
|
|
|
3 |
|
Hypoglycemic Agents |
|
Phase 4 |
|
|
|
4 |
|
Satavaptan |
Investigational |
Phase 3 |
|
185913-78-4 |
158348 |
Synonyms:
[<sup>3</sup>H]-SR121463A
1-(4-(N-Tert-butylcarbamoyl)-2-methoxybenzenesulfonyl)-5-ethoxy-3-spiro-(4-(2-morpholinoethoxy)cyclohexane)indol-2-one fumarate
1-(4-(N-Tert-butylcarbamoyl)-2-methoxybenzenesulfonyl)-5-ethoxy-3-spiro(4-(2-morpholinoethoxy)cyclohexane)indoline-2-one, phosphate monohydrate cis-isomer
AQUILDA
N-Tert-butyl-4-({5'-ethoxy-4-[2-(morpholin-4-yl)ethoxy]-2'-oxo-1',2'-dihydrospiro[cyclohexane-1,3'-indole]-1'-yl}sulfonyl)-3-methoxybenzene-1-carboximidate
N-Tert-butyl-4-({5'-ethoxy-4-[2-(morpholin-4-yl)ethoxy]-2'-oxo-1',2'-dihydrospiro[cyclohexane-1,3'-indole]-1'-yl}sulphonyl)-3-methoxybenzene-1-carboximidate
N-Tert-butyl-4-({5'-ethoxy-4-[2-(morpholin-4-yl)ethoxy]-2'-oxo-1',2'-dihydrospiro[cyclohexane-1,3'-indole]-1'-yl}sulphonyl)-3-methoxybenzene-1-carboximidic acid
|
SATAVAPTAN
SR 121463
SR 121463A|SR-121463B|SR-121463F|SR121463A
SR-121463
SR-121463A
SR-121463B
SR-121463F
|
|
5 |
|
Pharmaceutical Solutions |
|
Phase 2, Phase 3 |
|
|
|
6 |
|
Deamino Arginine Vasopressin |
|
Phase 2, Phase 3 |
|
|
|
7 |
|
Carbamide peroxide |
Approved |
Phase 2 |
|
124-43-6 |
|
Synonyms:
Carbamide peroxide
Hydrogen peroxide carbamide
Urea dioxide
|
Urea hydrogen peroxide
Urea peroxide
|
|
8 |
|
Fludrocortisone |
Approved, Investigational |
|
|
127-31-1 |
31378 |
Synonyms:
(8S,9R,10S,11S,13S,14S,17R)-9-FLUORANYL-10,13-DIMETHYL-11,17-BIS(OXIDANYL)-17-(2-OXIDANYLETHANOYL)-1,2,6,7,8,11,12,14,15,16-DECAHYDROCYCLOPENTA[A]PHENANTHREN-3-ONE
(8S,9R,10S,11S,13S,14S,17R)-9-FLUORO-11,17-DIHYDROXY-17-(2-HYDROXY-1-OXOETHYL)-10,13-DIMETHYL-1,2,6,7,8,11,12,14,15,16-DECAHYDROCYCLOPENTA[A]PHENANTHREN-3-ONE
(8S,9R,10S,11S,13S,14S,17R)-9-FLUORO-11,17-DIHYDROXY-17-(2-HYDROXYACETYL)-10,13-DIMETHYL-1,2,6,7,8,11,12,14,15,16-DECAHYDROCYCLOPENTA[A]PHENANTHREN-3-ONE
(8S,9R,10S,11S,13S,14S,17R)-9-FLUORO-17-GLYCOLOYL-11,17-DIHYDROXY-10,13-DIMETHYL-1,2,6,7,8,11,12,14,15,16-DECAHYDROCYCLOPENTA[A]PHENANTHREN-3-ONE
9 alpha Fludrohydrocortisone
9 alpha Fluoro 17 hydroxycorticosterone
9 alpha Fluorohydrocortisone
9 alpha-Fluoro-17-hydroxycorticosterone
9 alpha-Fluorohydrocortisone
9 Fluoro 17 hydroxycortisone
9 Fluorocortisol
9 Fluorohydrocortisone
9α-Flourocortisol|Florinef®
9a-FLUOROCORTISOL
9ALPHA-FLUOROCORTISOL
9-Fluoro-17-hydroxycortisone
9-Fluorocortisol
|
9-Fluorohydrocortisone
9Α-FLOUROCORTISOL
9Α-fluorocortisol
Astonin
Astonin H
Astonin merck
Astonin-H
FCOL
FLORINEF
FLUDROCORTISON
Fludrocortisona
FLUDROCORTISONE
Fludrocortisonum
FLUOHYDROCORTISONE
Merck brand OF fludrocortisone
Merck, astonin
|
|
9 |
|
Antipsychotic Agents |
|
|
|
|
|
10 |
|
Psychotropic Drugs |
|
|
|
|
|
11 |
|
Tea |
|
|
|
|
|
12 |
|
diuretics |
|
|
|
|
|
Interventional clinical trials:
(show all 32)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Effects of the SGLT2 Inhibitor Empagliflozin in Patients With Euvolemic and Hypervolemic Hyponatremia - a Multicentric Randomized Double-blind Placebo-controlled Trial (the EMPOWER Study) |
Recruiting |
NCT04447911 |
Phase 4 |
Empagliflozin 25 MG;Placebo |
2 |
Urinary Aquaporine 2 in Patients With Syndrome of Inappropriate ADH-secretion Caused by Treatment With Antiepileptic Medicine |
Withdrawn |
NCT00298753 |
Phase 4 |
|
3 |
Effects of Empagliflozin an SGLT2-Inhibitor on Healthy Volunteers With Induced Hypotonic Hyponatremia - the DIVE Study |
Completed |
NCT02729766 |
Phase 2, Phase 3 |
Empagliflozin 25mg Tbl;Placebo P-Tablet |
4 |
A Multicenter, Uncontrolled, Open-label, Dose-titration Trial to Investigate the Efficacy and Safety of Tolvaptan Tablets in Patients With Hyponatremia in Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) |
Completed |
NCT03048747 |
Phase 3 |
Tolvaptan Oral Tablet |
5 |
Effects of the SGLT2-inhibitor Empagliflozin on Patients With Chronic SIADH - the SANDx Study |
Completed |
NCT03202667 |
Phase 2, Phase 3 |
Empagliflozin 25mg;Placebo |
6 |
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of the Effects of Titrated Oral Tolvaptan Tablets in Patients With Hyponatremia |
Completed |
NCT00072683 |
Phase 3 |
tolvaptan |
7 |
A Randomized, Double-Blind, Placebo-Group, Multicenter Study Evaluating the Efficacy and Safety of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion |
Completed |
NCT00264927 |
Phase 3 |
SR121463B |
8 |
Multicenter, Randomized, Double-blind, Placebo-controlled, Efficacy and Safety Study of the Effects of Titrated Oral Tolvaptan Tablets in Patients With Hyponatremia, Study 2 |
Completed |
NCT00201994 |
Phase 3 |
Tolvaptan |
9 |
An Open-Label, Multicenter Study Evaluating the Long-Term Safety and Efficacy of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion |
Completed |
NCT00264914 |
Phase 3 |
SR121463B |
10 |
Effects of the SGLT2-inhibitor Empagliflozin on Patients With SIADH - the SAND Study |
Completed |
NCT02874807 |
Phase 2, Phase 3 |
Empagliflozin |
11 |
A Double-Blind, Randomized, Placebo-Controlled Multicenter Study Evaluating the Efficacy and Safety of Two Doses of Satavaptan (SR121463B) Versus Placebo in Patients With Dilutional Hyponatremia Due to the Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) |
Terminated |
NCT00728091 |
Phase 3 |
Satavaptan;placebo |
12 |
Phase 3b, Multicenter, Randomized, Single-blind, Parallel Group Trial of the Effects of Titrated Oral SAMSCA(r) (Tolvaptan) 15, 30, or 60 mg QD Compared to Placebo Plus Fluid Restriction on Length of Hospital Stay and Symptoms in Subjects Hospitalized With Dilutional Hyponatremia |
Terminated |
NCT01227512 |
Phase 3 |
tolvaptan |
13 |
A Phase 1b, Multicenter, Pilot, Randomized, Double-blind Trial to Determine the Pharmacokinetics and Pharmacodynamics of Orally Administered Tolvaptan 3.75, 7.5, and 15 mg Tablets in Subjects With Syndrome of Inappropriate Antidiuretic Hormone Secretion |
Completed |
NCT02009878 |
Phase 1, Phase 2 |
tolvaptan |
14 |
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Escalation, Multicenter Study Evaluating the Efficacy and Safety of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion. |
Completed |
NCT00032734 |
Phase 2 |
satavaptan (SR121463B) |
15 |
Urea for Chronic Hyponatremia: A Pilot Study |
Recruiting |
NCT04588207 |
Phase 2 |
Urea |
16 |
A Multi-Centre, Multi-National, Observational Post-Authorisation Safety Study to Document the Drug Utilisation of Samsca and to Collect Information on the Safety of Samsca When Used in Routine Medical Practice |
Unknown status |
NCT01228682 |
|
Tolvaptan |
17 |
Is Hyponatraemia a Risk Factor for Mortality in Schizophrenic and Bipolar Patients? Protocol for a Bayesian Causal Inference Study |
Unknown status |
NCT04409626 |
|
|
18 |
Observational Cohort Study- The Clinical and Laboratory Characteristics of Recurrent Drug- Related |
Unknown status |
NCT01509170 |
|
|
19 |
Comparison of the Vasopressin-2 Antagonist Tolvaptan and Fluid Restriction in the Treatment of Hyponatremia Following Pituitary Surgery |
Completed |
NCT04119206 |
|
|
20 |
Standardization of Fluids in Inpatient Settings |
Completed |
NCT03924674 |
|
|
21 |
A Prospective, Observational Study Measuring Sodium Improvement and Outcomes in Cancer Patients Treated for Moderate to Severe Hyponatremia Secondary to SIADH in Italy |
Completed |
NCT02573077 |
|
|
22 |
Water Load Test Value for Hyponatremia Due to a Syndrome of Inappropriate Antidiuresis (SIAD) |
Completed |
NCT04256499 |
|
|
23 |
A Non Interventional, Retrospective Study on Real World Usage and Treatment Outcomes of Patients Treated With Tolvaptan for Hyponatraemia Due to the SIADH. |
Completed |
NCT02545101 |
|
|
24 |
An Observational, Retrospective Study to Describe the Extent of Adherence to the Spanish Society of Medical Oncology Algorithm for the Treatment of Hyponatraemia Secondary to SIADH in Oncology Patients in Spain (ALGA) |
Completed |
NCT02548845 |
|
|
25 |
Subclassification of the Syndrome of Inappropriate Antidiuresis Via Copeptin - What is the Genesis of ADH-independent SIADH? |
Completed |
NCT01341665 |
|
|
26 |
Changes in Serum Creatinine Levels Can Help Distinguish Hypovolemic From Euvolemic Hyponatremia |
Completed |
NCT04744987 |
|
|
27 |
Samsca Post-marketing General Drug Use-results Survey in Patients With Hyponatremia in Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) in Japan |
Recruiting |
NCT04790175 |
|
Tolvaptan (SAMSCA) |
28 |
Effect of Protein Supplementation on Plasma Sodium Levels and Urinary Urea Excretion in Patients With SIAD - a Monocentric Open- Label Proof-of-concept Study -The TREASURE Study |
Recruiting |
NCT04987385 |
|
|
29 |
Urea Therapy for Hyponatremia in Subarachnoid Hemorrhage |
Recruiting |
NCT04552873 |
|
Urea |
30 |
Asymptomatic Bacteriuria, Hyponatremia and Geri-atric Syndrome |
Recruiting |
NCT05055856 |
|
|
31 |
Use of Tolvaptan to Treat SIADH-induced Hyponatremia in Selected Patients With Acute Neurological Injuries |
Terminated |
NCT02545114 |
|
Tolvaptan |
32 |
Study of Nonedematous Hyponatremia and the Utility of Fractional Urate Excretion in Hyponatremia and Suspected Renal Salt Wasting Without Hyponatremia- |
Withdrawn |
NCT01425125 |
|
Tolvaptan in euvolemic hyponatremia |
|